Famous short-seller Andrew Left of Citron Research published a report Tuesday that predicted Lannett, a generic drug company that's one of the targets of a price-fixing investigation and other lawsuits, will be "the first pharma company to go bankrupt amid continuing drug pricing scrutiny."

If Lannett has to roll back its drug prices to where they were a few years ago, Left wrote, the drug maker will go belly up quickly because it will not generate enough cash to pay off its large debt load. Lannett is reliant on only a handful of its drugs, like thyroid medicine levothyroxine, for most of its business. A Lannett spokesman declined to comment.

Why it matters: Other drug companies that took on major debt to make deals, with the expectation of raising prices later, could find themselves in a similar situation. But this, of course, assumes Trump and Congress both agree to take on the drug industry.

Go deeper

The childless vaccine

Illustration: Eniola Odetunde/Axios

It'll likely be a long time before children are vaccinated against COVID-19, even though vaccinating kids could eventually play an integral role in reducing the virus' spread.

The big picture: None of the leading contenders in the U.S. are being tested for their effectiveness in children. Even once one of them gains authorization from the Food and Drug Administration, there will only be a limited number of available doses.

Progressives bide time for a Biden victory

Illustration: Sarah Grillo/Axios

Progressive Democrats want to beat President Trump so badly that they're tabling their apathy about Joe Biden — organizing hard to get him into office, only to fight him once elected.

Why it matters: That's a big difference from 2016, when progressives’ displeasure with Hillary Clinton depressed turnout and helped deliver the White House to Trump.

Election influence operations target journalists

Illustration: Aïda Amer/Axios

Foreign and domestic actors looking to influence the 2020 election are trying to trick real reporters into amplifying fake storylines. This tactic differs from 2016, when bad actors used fake accounts and bots to amplify disinformation to the population directly.

Why it matters: The new strategy, reminiscent of spy operations during the Cold War, is much harder for big tech platforms to police and prevent.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!